Latest News
Boehringer Ingelheim, three research institutes to co-discover therapeutic targets within ubiquitin system
22 July 2014 - 22 July 2014 - German pharmaceutical group Boehringer Ingelheim said Tuesday it had entered into a research partnership with Canada's University of Toronto via the Toronto Recombinant Antibody Centre (TRAC), along with Toronto-based University Health Network and US Mount Sinai Hospital for the characterisation of novel therapeutic targets in the field of ubiquitin signalling biology.

Alterations of the ubiquitin system are associated with numerous common diseases including cancer, diabetes, inflammation and certain central nervous system disorders. Boehringer Ingelheim will collaborate with researchers in the Toronto academic community to investigate multiple therapeutic concepts within the ubiquitin system, which holds potential to create many drug targets.

As part of the alliance, the research capabilities of the company and the research institutes will be combined to provide new starting points for drug discovery in a multi-year research programme centred on the development and characterisation of novel ubiquitin binding variants developed at TRAC.

The research programme will be spearheaded by Sachdev Sidhu at the University of Toronto.



 

 
Login
Username:

Password: